RT Journal Article
SR Electronic
T1 COVID-19 and first trimester spontaneous abortion: a case-control study of 225 pregnant patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.19.20135749
DO 10.1101/2020.06.19.20135749
A1 Stefano Cosma
A1 Andrea Carosso
A1 Jessica Cusato
A1 Fulvio Borella
A1 Marco Carosso
A1 Marialuisa Bovetti
A1 Claudia Filippini
A1 Antonio D’Avolio
A1 Valeria Ghisetti
A1 Giovanni Di Perri
A1 Chiara Benedetto
YR 2020
UL http://medrxiv.org/content/early/2020/06/20/2020.06.19.20135749.abstract
AB Background Evidence for the impact of COVID-19 during the second and the third trimester of pregnancy is limited to a relatively small series, while data on the first trimester are scant. With this study we evaluated COVID-19 infection as a risk factor for spontaneous abortion in first trimester of pregnancy.Methods Between February 22 and May 21, 2020, we conducted a case-control study at S. Anna Hospital, Turin, among first trimester pregnant women, paired for last menstruation. The cumulative incidence of COVID-19 was compared between women with spontaneous abortion (case group, n=100) and those with ongoing pregnancy (control group, n=125). Current or past infection was determined by detection of SARS-CoV-2 from nasopharingeal swab and SARS- CoV-2 IgG/IgM antibodies in blood sample. Patient demographics, COVID-19-related symptoms, and the main risk factors for abortion were collected.Findings Twenty-three (10.2%) of the 225 women tested positive for COVID-19 infection. There was no difference in the cumulative incidence of COVID-19 between the cases (11/100, 11%) and the controls (12/125, 9.6%) (p=0.73). Logistic regression analysis confirmed that COVID-19 was not an independent predictor of abortion (1.28 confidence interval 0.53-3.08).Interpretation COVID-19 infection during the first trimester of pregnancy does not appear to predispose to abortion; its cumulative incidence did not differ from that of women with ongoing pregnancy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementResearch university fundsAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Review Board of the City of Health and Science of Torino (Reference number: 00171/2020)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe dataset generated during during the current study is available from the corresponding author on reasonable request.